"pasotuxizumab" meaning in All languages combined

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "",
        "3": "-tu-",
        "4": "-xi-",
        "5": "-zumab",
        "t2": "tumor",
        "t3": "chimeric",
        "t4": "humanized monoclonal antibody"
      },
      "expansion": "[Term?] + -tu- (“tumor”) + -xi- (“chimeric”) + -zumab (“humanized monoclonal antibody”)",
      "name": "af"
    }
  ],
  "etymology_text": "From [Term?] + -tu- (“tumor”) + -xi- (“chimeric”) + -zumab (“humanized monoclonal antibody”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "pasotuxizumab (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms interfixed with -tu-",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms interfixed with -xi-",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms suffixed with -zumab",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Healthcare",
            "Fundamental",
            "Health",
            "Body"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2021 May 26, Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu, “The landscape of bispecific T cell engager in cancer treatment”, in Biomarker Research, volume 9, →DOI, article 38, page 4:",
          "text": "Pasotuxizumab (AMG 212) is a canonical BiTE antibody targeting PSMA [77]. The anti-tumor activity which was defined by PSA level decrease was dose-dependent. Two patients achieved long-term PSA responses with more than 1 year of treatment at doses of 40 μg/d and 80 μg/d, respectively.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A bi-specific T-cell engager monoclonal antibody developed for the treatment of prostate cancer."
      ],
      "id": "en-pasotuxizumab-en-noun-0K7f9Tkr",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "monoclonal antibody",
          "monoclonal antibody"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "prostate",
          "prostate"
        ],
        [
          "cancer",
          "cancer"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A bi-specific T-cell engager monoclonal antibody developed for the treatment of prostate cancer."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "pasotuxizumab"
}

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "",
        "3": "-tu-",
        "4": "-xi-",
        "5": "-zumab",
        "t2": "tumor",
        "t3": "chimeric",
        "t4": "humanized monoclonal antibody"
      },
      "expansion": "[Term?] + -tu- (“tumor”) + -xi- (“chimeric”) + -zumab (“humanized monoclonal antibody”)",
      "name": "af"
    }
  ],
  "etymology_text": "From [Term?] + -tu- (“tumor”) + -xi- (“chimeric”) + -zumab (“humanized monoclonal antibody”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "pasotuxizumab (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English term requests",
        "English terms interfixed with -tu-",
        "English terms interfixed with -xi-",
        "English terms suffixed with -zumab",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry",
        "Pages with entries",
        "en:Pharmaceutical drugs"
      ],
      "examples": [
        {
          "ref": "2021 May 26, Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu, “The landscape of bispecific T cell engager in cancer treatment”, in Biomarker Research, volume 9, →DOI, article 38, page 4:",
          "text": "Pasotuxizumab (AMG 212) is a canonical BiTE antibody targeting PSMA [77]. The anti-tumor activity which was defined by PSA level decrease was dose-dependent. Two patients achieved long-term PSA responses with more than 1 year of treatment at doses of 40 μg/d and 80 μg/d, respectively.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A bi-specific T-cell engager monoclonal antibody developed for the treatment of prostate cancer."
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "monoclonal antibody",
          "monoclonal antibody"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "prostate",
          "prostate"
        ],
        [
          "cancer",
          "cancer"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A bi-specific T-cell engager monoclonal antibody developed for the treatment of prostate cancer."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "pasotuxizumab"
}